Betahistine: English spelling of betahistin
Betahistine is the English spelling of the substance betahistin. In English-language literature, international summaries of product characteristics and some brand names (such as Serc) this form is found. The German spelling betahistin is common in Germany and Austria. Pharmacologically the same substance is meant: a histamine analogue with characteristic action in the inner ear and CNS.
Betahistine was introduced in 1965 for the treatment of Menière's disease. Despite long clinical experience, the evidence on efficacy is controversial: current Cochrane reviews show conflicting results for the symptomatic treatment of Menière's disease, while in clinical practice many patients report improvement of vertigo and tinnitus. Betahistine therefore remains standard in many European ENT guidelines.
Mechanism of action
Betahistine acts on histamine receptors with a mixed profile:
- Weak agonist at H1 receptors of peripheral endothelial cells, leading to vasodilation in the inner ear microcirculation
- Strong antagonist at presynaptic H3 autoreceptors, increasing histamine release in the CNS
Vasodilation in the stria vascularis of the inner ear presumably improves perfusion of the inner hair cells and reduces pressure in the endolymphatic compartment. Central histaminergic enhancement influences vestibular processing in the brain stem and may facilitate adaptation to disturbed vestibular input.
Betahistine is mainly metabolised to 2-pyridylacetic acid, which is excreted by the kidneys. Half-life is 3 to 4 hours; duration of action is correspondingly limited, requiring multiple daily doses.
Indications
- Menière's disease: main indication, reduction of vertigo attacks, tinnitus and hearing loss
- Vestibular vertigo: for peripheral vestibular disorders that cannot be clearly classified
- Off-label uses: chronic tinnitus, vestibular migraine (controversial), promotion of adaptation after vestibular neuritis
Betahistine is not suitable for treating other forms of vertigo such as central vertigo syndromes, benign paroxysmal positional vertigo or vertigo of cardiac origin. Correct diagnosis is a prerequisite for efficacy.
Dosing and administration
Standard dose: 8 to 16 mg three times daily, total 24 to 48 mg per day. With good tolerability, an increase up to 48 mg per day is possible.
Titration: stepwise titration is recommended to reduce gastrointestinal complaints.
Tablets are taken with meals and plenty of liquid to avoid stomach discomfort.
Assess therapy effect: full effect appears after 2 to 3 months. With insufficient improvement, reassess therapy after at least 3 months, possibly review the diagnosis or consider other therapies.
Side effects
Common: nausea, abdominal pain, indigestion, headache, rash, pruritus.
Uncommon: allergic reactions, rhinorrhoea, tachycardia, fatigue.
Rare: worsening of asthma in predisposed patients, reactivation of gastric ulcer, Quincke's oedema.
Important points:
- Overall very good tolerability profile
- Caution in bronchial asthma, since theoretically bronchoconstriction via H1 activation is possible
- With active gastric ulcer or history of gastric ulcer, betahistine should only be used under medical supervision
Interactions
- Antihistamines (H1 antagonists): antagonistic effect, since betahistine acts as H1 agonist; avoid combination if possible, otherwise both are weakened
- MAO inhibitors: theoretical inhibition of betahistine breakdown, rarely clinically relevant
- Salbutamol and other asthma drugs: mutual effects scarcely documented, caution in asthmatics
- Antibiotics and other substances: no relevant interactions known
Special considerations
Pregnancy: insufficiently studied, hence cautious use. With a clear indication, individual judgement.
Breastfeeding: data lacking, avoid use if possible.
Contraindications: known hypersensitivity, phaeochromocytoma, first-trimester pregnancy without clear indication.
Children: experience limited; in Germany no broad approval for children under 18.
Bronchial asthma: theoretical risk of bronchoconstriction through H1 activation; close monitoring in asthmatics.
Therapy success and patience: patients with Menière's disease should develop realistic expectations. The effect appears slowly and is mainly aimed at reducing vertigo attacks rather than improving hearing loss. Accompanying vestibular rehabilitation may be useful.
Lifestyle adjustments: in Menière's disease, reducing salt, alcohol, caffeine and stress can favourably influence symptoms. Drug therapy is only one element of the overall concept.
Related substances
- Betahistin, German spelling of the same substance
- Cinnarizine, alternative vertigo therapy
- Dimenhydrinate, classic antiemetic for motion sickness and vertigo
- Pridinol, anticholinergic with anti-vertigo properties
Frequently asked questions
Is the substance called betahistine or betahistin?
Betahistine is the English spelling, betahistin is the German form. Both refer to the same substance from the histamine analogue class.
How quickly does betahistine work in Menière's disease?
Improvement usually appears only after several weeks to months. The substance aims at reducing the frequency and severity of vertigo attacks rather than acute relief. For acute attacks, other drugs such as antihistamines or anticholinergics are used.
Is betahistine safe in asthma?
Theoretically, weak H1 agonism could trigger bronchoconstriction. In practice betahistine is used in asthmatics under observation, with no frequent clinical problems documented. With acute asthma symptoms, therapy should be reconsidered.
Can I take betahistine long term?
Yes, betahistine is designed as long-term therapy. Treatment can be continued for months to years; regular checks of efficacy and tolerability make sense. With prolonged symptom freedom, a tapering attempt can be considered.
Sources
- EMA European Medicines Agency
- BfArM Federal Institute for Drugs and Medical Devices
- AWMF guidelines vertigo and Menière's disease
- Gelbe Liste betahistin monograph
Legal notice and disclaimer
The information on this page is provided for general information purposes only and does not constitute medical advice, diagnosis or treatment recommendation. It does not replace the advice of a licensed physician or pharmacist. Medicines should only be used after a doctor's prescription or pharmacy supply. All information is based on summaries of product characteristics and accepted scientific sources at the time of writing; the current SmPC of the manufacturer is always decisive. Sanoliste accepts no liability for completeness, timeliness or accuracy. In a medical emergency, dial the emergency number 112.